<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02150967</url>
  </required_header>
  <id_info>
    <org_study_id>CBGJ398X2204</org_study_id>
    <secondary_id>2013-005085-19</secondary_id>
    <nct_id>NCT02150967</nct_id>
  </id_info>
  <brief_title>A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma</brief_title>
  <official_title>A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>QED Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helsinn Healthcare SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>QED Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open label, single arm phase II study evaluating BGJ398 anti-tumor&#xD;
      activity in advanced or metastatic cholangiocarcinoma patients with Fibroblast Growth Factor&#xD;
      receptor (FGFR) genetic alterations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult patients with histologically or cytologically confirmed advanced or metastatic&#xD;
      cholangiocarcinoma with FGFR2 gene fusions or translocations or other FGFR genetic&#xD;
      alterations who have evidence of radiologic progression following a cisplatin-and&#xD;
      gemcitabine-containing regimen for advanced disease or a gemcitabine-containing regimen for&#xD;
      those who are considered intolerant to cisplatin will be enrolled. Up to approximately 160&#xD;
      adult patients over age 18, both male and female will be enrolled. Three cohorts of patients&#xD;
      comprise the study population:&#xD;
&#xD;
      Cohort 1: patients with FGFR2 gene fusions or translocations and other FGFR genetic&#xD;
      alterations enrolled under the original protocol and amendment 1.&#xD;
&#xD;
      Cohort 2: patients with FGFR genetic alterations other than FGFR2 gene fusions or&#xD;
      translocations.&#xD;
&#xD;
      Cohort 3: patients with FGFR2 gene fusions or translocations who have received a prior FGFR&#xD;
      inhibitor.&#xD;
&#xD;
      All patients will receive oral BGJ398, once daily, on a three weeks on (21 days), one week&#xD;
      off (7 days) schedule. One treatment cycle will consist of 28 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 23, 2014</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Overall response rate (ORR) is defined as the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR), as per RECIST version 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Overall Survival (OS) is defined as the time from the date of start of treatment to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Progression free survival (PFS) is defined as the date of the start of treatment to the date of the event defined as the first documented progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response</measure>
    <time_frame>up to 24 months</time_frame>
    <description>The best overall response will be summarized by the proportion of patients having a best overall response of PR, CR, stable disease (SD) or PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Disease control rate (DCR) is the proportion of patients with a best overall response of CR or PR or stable disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events (AEs) and serious adverse events (SAEs) as a measure of safety and tolerability</measure>
    <time_frame>up to 24 months</time_frame>
    <description>To characterize the safety and tolerability of single agent BGJ398 by the type, frequency and severity of AEs &amp; SAEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Selected trough and 2-hr or 4-hr Plasma concentration profile</measure>
    <time_frame>up to 12 months</time_frame>
    <description>To determine selected trough and 2-hr or 4-hr plasma concentrations of BGJ398</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">143</enrollment>
  <condition>Advanced Cholangiocarcinoma</condition>
  <condition>FGFR2 Gene Mutation</condition>
  <arm_group>
    <arm_group_label>BGJ398 (infigratinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To estimate anti-tumor activity of BGJ398</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGJ398 (infigratinib)</intervention_name>
    <description>Capsule for oral use</description>
    <arm_group_label>BGJ398 (infigratinib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        - Adult patients with histologically or cytologically confirmed cholangiocarcinoma at the&#xD;
        time of diagnosis.&#xD;
&#xD;
        Patients with cancers of the gallbladder or ampulla of Vater are not eligible.&#xD;
&#xD;
        - Patients must have received at least one prior regimen containing gemcitabine with or&#xD;
        without cisplatin for advanced/ metastatic disease. Patient should have evidence of&#xD;
        progressive disease following prior regimen, or if prior treatment discontinued due to&#xD;
        toxicity must have continued evidence of measurable or evaluable disease.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Prior or current treatment with a MEK inhibitor (all cohorts), BGJ398/infigratinib&#xD;
             (all cohorts), or selective FGFR inhibitor (Cohorts 1 and 2 only).&#xD;
&#xD;
          -  insufficient organ function&#xD;
&#xD;
               -  Absolutely Neutrophil Count (ANC) &lt; 1,000/mm3 [1.0 x 109/L]&#xD;
&#xD;
               -  Platelets &lt; 75,000/mm3 [75 x 109/L]&#xD;
&#xD;
               -  Hemoglobin &lt; 109.0 g/dL&#xD;
&#xD;
               -  Total bilirubin &gt; 1.5x ULN&#xD;
&#xD;
               -  Aspartate aminotransferase/glutamic oxaloacetic transaminase/GOT (AST/SGOT) and&#xD;
                  Alanine aminotransferase/glutamic pyruvic transaminase/GPT (ALT/SGPT) &gt; 2.5x ULN&#xD;
                  (AST and ALT) &gt; 5x upper limit of normal (ULN) in the presence of liver&#xD;
                  metastases)&#xD;
&#xD;
               -  Serum creatinine &gt; 1.5x ULN and a calculated or measured creatinine clearance &lt;&#xD;
                  45 mL/min&#xD;
&#xD;
               -  Inorganic phosphorus outside of normal limits&#xD;
&#xD;
               -  Total and ionized serum calcium outside of normal limits&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>QED Therapeutics</last_name>
    <role>Study Director</role>
    <affiliation>QED Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Ancona</city>
        <state>AN</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Volzhskiy</city>
        <zip>404133</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>8908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Taipei</city>
        <state>Taiwan ROC</state>
        <zip>10041</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Zhunan</city>
        <zip>35053</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Khon Kaen</city>
        <state>THA</state>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Bebington</city>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 12, 2014</study_first_submitted>
  <study_first_submitted_qc>May 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2014</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cholangiocarcinoma,</keyword>
  <keyword>FGFR2 gene fusion,</keyword>
  <keyword>FGFR genetic alteration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infigratinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

